Cardiovascular Effects of Longer-Term, High-Dose OROS Methylphenidate in Adolescents with Attention Deficit Hyperactivity Disorder

Journal of Pediatrics

Volumn 155, Issue 1, 2009, Pages

  Hammerness, Paul ^a   Wilens, Timothy ^a   Mick, Eric ^a   Spencer, Thomas ^a   Doyle, Robert ^a   McCreary, Michelle ^a   Becker, Judith ^a   Biederman, Joseph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT; ADULT; ANXIETY; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHILD; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; IRRITABILITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; STOMACH PAIN; SWEATING; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; WEIGHT REDUCTION;

EID: 67649797366     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2009.02.008     Document Type: Article

References (30)

1. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46 (2007) 894-921
2. Brown R.T., Amler R.W., Freeman W.S., Perrin J.M., Stein M.T., Feldman H.M., et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 115 (2005) e749-e757
3. Nissen S.E. ADHD Drugs and Cardiovascular Risk. N Engl J Med 354 (2006) 1445-1448
4. Biederman J., Spencer T.J., Wilens T.E., Prince J.B., and Faraone S.V. Treatment of ADHD with stimulant medications: response to Nissen Perspective in the New England Journal of Medicine. J Am Acad Child Adolesc Psychiatry 45 (2006) 1147-1150
5. Knight M. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death. Pediatrics 119 (2007) 154-155
6. Wilens T., Spencer T., Prince J., and Biederman J. Stimulants and sudden death: what is a physician to do?. Pediatrics 118 (2006) 1215-1219
7. Wilens T., McBurnett K., Bukstein O., McGough J., Greenhill L., Lerner M., et al. Multisite, controlled trial of OROS® methylphenidate (CONCERTA®) in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 160 (2006) 82-90
8. Findling Rl BJ, Boellner S, Kerkering J. Cardiovascular effects of MTS in pediatric patients. American Psychiatric Association Annual Meeting. May 23, 2007. San Diego, California.
9. Findling R.L., Biederman J., Wilens T., Spencer T., McGough J., Lopez F.A., et al. Short and long-term cardiovascular effects of mixed amphetamine salts extended release (Adderall XR) in Children. J Pediatr 147 (2005) 348-354
10. Winterstein A.G., Gerhard T., Shuster J., Johnson M., Zito J.M., and Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 120 (2007) e1494-e1501
11. Perrin J.M., Friedman R.A., and Knilans T.K. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122 (2008) 451-453
12. Wilens T., McBurnett K., Stein M., Lerner M., Spencer T., and Wolraich M. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 44 (2005) 1015-1023
13. Donner R., Michaels M.A., and Ambrosini P.J. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder. Biol Psychiatry 61 (2007) 706-712
14. Wilens T.E., Spencer T.J., and Biederman J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in adolescents with ADHD. CNS Spectrums 10 (2005) 22-30
15. Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am 17 (2008) 459-474
16. Findling R.L., Short E.J., and Manos M.J. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 40 (2001) 525-529
17. McGough J.J., McBurnett K., Bukstein O., Wilens T.E., Greenhill L., Lerner M., et al. Once-daily OROS((R)) methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 16 (2006) 351-356
18. Pelham W.E., Gnagy E.M., Burrows-Maclean L., Williams A., Fabiano G.A., Morrisey S.M., et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107 (2001) E105
19. Stein M.A., Sarampote C.S., Waldman I.D., Robb A.S., Conlon C., Pearl P.L., et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112 (2003) e404
20. Wilens T.E., Biederman J., and Lerner M. The Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 24 (2004) 36-41
21. Vetter V.L., Elia J., Erickson C., Berger S., Blum N., Uzark K., et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117 (2008) 2407-2423
22. Gutgesell H., Atkins D., Barst R., Buck M., Franklin W., Humes R., et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs. Circulation 23 (1999) 979-982
23. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114 (2004) 555-576
24. Wilens T., Spencer T., and Biederman J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended-release in adolescents with ADHD. CNS Spectrums 10 (2005) 22-30
25. Muntner P., He J., Cutler J.A., Wildman R.P., and Whelton P.K. Trends in blood pressure among children and adolescents. JAMA 291 (2004) 2107-2113
26. Falkner B., Gidding S.S., Ramirez-Garnica G., Wiltrout S.A., West D., and Rappaport E.B. The relationship of body mass index and blood pressure in primary care pediatric patients. J Pediatr 148 (2006) 195-200
27. Jago R., Harrell J.S., McMurray R.G., Edelstein S., El Ghormli L., and Bassin S. Prevalence of abnormal lipid and blood pressure values among an ethnically diverse population of eighth-grade adolescents and screening implications. Pediatrics 117 (2006) 2065-2073
28. Sorof J.M., Lai D., Turner J., Poffenbarger T., and Portman R.J. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 113 (2004) 475-482
29. Park M.K., Menard S.W., and Schoolfield J. Oscillometric blood pressure standards for children. Pediatr Cardiol 26 (2005) 601-607
30. Park M.K., Menard S.W., and Yuan C. Comparison of auscultatory and oscillometric blood pressures. Arch Pediatr Adolesc Med 155 (2001) 50-53